Top 21 Pharmaceuticals Companies
21 Pharmaceuticals companies with latest reported revenue, headquarters and links to their sourced company profiles.
21 of these companies have a latest reported revenue figure, shown on their profiles with its fiscal year and source. This directory does not publish a combined sector revenue, because parent companies and subsidiaries and different revenue measures overlap.
Pharmaceuticals industry overview
This index covers 21 Pharmaceuticals companies analyzed through their revenue history, business model mechanics, and competitive positioning. All financial data is sourced from official SEC filings, annual reports, and verified investor relations disclosures. Profiles are reviewed by our editorial team before publication to ensure data accuracy and analytical depth.
This hub currently maps 21 organizations to Pharmaceuticals. The revenue spotlight uses each company's latest disclosed figure, converts non-US reporting currencies only for approximate ordering, and links to the underlying company profile for fiscal-year and source context.
Top companies in this industry (by latest revenue)
Johnson & Johnson: $94.2B FY2025 sales, $101.1B 2026 guidance, CEO Joaquin Duato, $5.5B talc settlement plan, DePuy Synthes separation and key rivals.
Roche profile: ~$73.8B 2025 sales, H1 2026 results, CEO Thomas Schinecker, family ownership, pharma and diagnostics model, deals and competitors.
Eli Lilly: $65.2B 2025 revenue, $23.0B Q2 2026 sales, $85-87B 2026 guidance, CEO David Ricks, Mounjaro, Zepbound, Foundayo and rivals.
Merck profile updated for FY2025 sales, net income, 75,000 employees, Robert M. Davis, Keytruda, Winrevair, Animal Health, vaccines, and patent-cliff strategy.
Pfizer company profile covering FY2025 revenue, CEO Albert Bourla, history, business model, competitors, and strategy.
AbbVie profile: $61.2B FY2025 revenue, Abbott spin-off history, CEO Robert A. Michael, Skyrizi, Rinvoq, Humira, Botox, and rivals.
AstraZeneca company profile covering FY2025 revenue, profit, employees, CEO Pascal Soriot, biopharmaceutical business model, and pipeline strategy.
Novartis revenue was $54.5B in FY2025 net sales; Q2 2026 sales were $14.4B. See how Novartis makes money, who owns it, CEO Vas Narasimhan, and competitors.
Bayer company profile covering history, FY2025 revenue of ~$51.5B, founders, CEO Bill Anderson, business model, competitors and official sources.
Sanofi profile: ~$49.3B 2025 net sales, Q2 2026 results, CEO Belén Garijo, how Sanofi makes money from Dupixent and vaccines, owners and competitors.
All 21 companies in this industry (A-Z)
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca PLC
- Bausch Health Companies Inc.
- Bayer AG
- Biogen Inc.
- BioNTech SE
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- GSK plc
- Johnson & Johnson
- Merck & Co., Inc.
- Moderna, Inc.
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Sanofi S.A.
- Vertex Pharmaceuticals Incorporated
First 10 companies
Suggested company profiles
Moderna reported FY2025 revenue of $1.94B and a $2.82B net loss. See how Moderna makes money, who leads and owns it, its competitors, and 2026 milestones.
Sanofi profile: ~$49.3B 2025 net sales, Q2 2026 results, CEO Belén Garijo, how Sanofi makes money from Dupixent and vaccines, owners and competitors.
Novo Nordisk profile: FY2025 sales of DKK 309.1B ($46B), CEO Mike Doustdar, Wegovy pill launch, Novo Nordisk Foundation ownership, competitors and 2026 outlook.
Merck profile updated for FY2025 sales, net income, 75,000 employees, Robert M. Davis, Keytruda, Winrevair, Animal Health, vaccines, and patent-cliff strategy.
GSK profile: £32.7B 2025 sales, H1 2026 results, CEO Luke Miels, how GSK makes money (HIV, Shingrix, Trelegy), the $10.6B Nuvalent deal and rivals Pfizer
Roche profile: ~$73.8B 2025 sales, H1 2026 results, CEO Thomas Schinecker, family ownership, pharma and diagnostics model, deals and competitors.
Novartis revenue was $54.5B in FY2025 net sales; Q2 2026 sales were $14.4B. See how Novartis makes money, who owns it, CEO Vas Narasimhan, and competitors.
Johnson & Johnson: $94.2B FY2025 sales, $101.1B 2026 guidance, CEO Joaquin Duato, $5.5B talc settlement plan, DePuy Synthes separation and key rivals.
Pfizer company profile covering FY2025 revenue, CEO Albert Bourla, history, business model, competitors, and strategy.
Top Pharmaceuticals Head-to-Head Comparisons
Abbvie vs Amgen
AbbVie is the bigger company by revenue, but Amgen earned more profit in 2025. AbbVie reported $61.2 billion of revenue against Amgen's $36.8 billion, while Amgen's net income was $7.7 billion, about 1.8 times AbbVie's $4.2 billion. AbbVie was worth about twice as much on September 29, 2026: about $465.3 billion against $229.0 billion.
Abbvie vs Eli Lilly
Eli Lilly is now larger by revenue, profit and market value. Lilly reported $65.2 billion of revenue for 2025, up 44.7%, against AbbVie's $61.2 billion, up 8.6%. Lilly's net income was $20.6 billion against AbbVie's $4.2 billion, and on September 29, 2026 Lilly was worth about $1.06 trillion, more than twice AbbVie's $465.3 billion.
Abbvie vs Johnson And Johnson
Johnson & Johnson is bigger and far more profitable: it reported $94.193 billion in FY2025 sales against AbbVie's $61.160 billion, and a 28.5% net margin against AbbVie's 6.9%. AbbVie grew faster in FY2025, with revenue up 8.6% versus J&J's 6.0%, driven by its immunology drugs Skyrizi and Rinvoq. By market value, J&J was worth about $643.9 billion in September 2026, versus roughly $465.8 billion for AbbVie.
Abbvie vs Novartis
AbbVie is slightly larger by revenue, and Novartis is far more profitable. AbbVie reported $61.2 billion of net revenues for 2025, while Novartis reported total revenues of $56.7 billion, including $54.5 billion of net sales. Novartis's net income was $14.0 billion against AbbVie's $4.2 billion, but AbbVie's market value was higher: about $465.3 billion against $275.3 billion on September 29, 2026.
Astrazeneca vs Pfizer
Pfizer is bigger by revenue and AstraZeneca is bigger by market value and profit. Pfizer reported $62.58 billion in revenue for fiscal 2025 (ended December 31, 2025), compared with AstraZeneca's $58.74 billion in Total Revenue for the same year, but AstraZeneca's profit for the year was $10.23 billion against Pfizer's net income of $7.77 billion. As of late September 2026, AstraZeneca's market capitalization of about $257.8 billion was roughly $97 billion higher than Pfizer's $160.3 billion, a reversal of 2014, when Pfizer tried to buy AstraZeneca outright for about $117 billion.
Biontech vs Moderna
Moderna is the bigger company by market value, worth about $72.7 billion versus BioNTech's $24.69 billion as of September 30, 2026. BioNTech is bigger by revenue, reporting ~$3.24 billion (€2.87 billion) in FY2025 against Moderna's $1.94 billion, and posted a smaller net loss (~$1.29 billion (€1.14 billion) versus $2.82 billion). Moderna also has more approved products, including mFLUSIVA, the first mRNA flu vaccine, approved August 5, 2026, while BioNTech still relies mainly on declining Comirnaty royalties and an unapproved oncology pipeline.
Related industries
Editorial Methodology
We use company filings, annual reports, company statements and press reports, with primary sources preferred where available. Each financial row shows its recorded source. Full-year figures are separated from annualized run-rates, partial periods and forecasts; unaudited figures carry a label. Source detail varies by company, so check the linked material when the reporting basis matters.
Public companies may provide filings and annual reports. Private-company figures may come from statements or press coverage. A missing figure stays missing, and a source link should identify where its number came from.
We organize company records and review claims for strategic context, source quality and clarity. Pages show a review date where one is recorded.
Technical checks flag inconsistent figures and missing links. Editorial review of the underlying source remains necessary for claims those checks cannot verify.
